Robbins LLP says Embecta faces securities class action after stock drop
Robbins LLP says a securities class action targets Embecta Corp. over alleged misstatements about guidance and business performance before the company cut its outlook and dividend.
Robbins LLP said a securities class action has been filed against Embecta Corp. over allegations that the diabetes device maker misled investors about its financial outlook before a steep stock drop on May 5, 2026.
The suit says Embecta repeatedly reaffirmed its fiscal 2026 revenue guidance while failing to disclose information that, according to the complaint, showed the outlook was weaker than it had told investors. Robbins said the case covers shareholders who bought Embecta stock between Nov. 25, 2025, and May 4, 2026.
In its July 31 press release, Robbins said the complaint alleges Embecta and certain executives made materially false and misleading statements about business prospects, financial performance, second-quarter and full-year 2026 guidance, and the strength of the company's pen needle segment. The firm said the alleged truth emerged when Embecta reported it had missed second-quarter 2026 guidance and cut fiscal 2026 guidance by about 46%.
Robbins also said Embecta cited weakness in pen needle sales when it lowered its outlook and announced a 93% reduction in its dividend. The release said the stock fell more than 57% to $3.90 per share on May 5, 2026.
According to Robbins, shareholders who want to serve as lead plaintiff must submit papers to the court by Aug. 17, 2026. The firm said investors who suffered losses may be eligible to participate in the case, which it said is on a contingency-fee basis.
Robbins included a quote from Brian J. Robbins, who said companies should be governed responsibly, fiduciaries held accountable, and shareholders deserve transparency and fairness.
Embecta was not quoted in the Robbins press release provided in the research brief, and the brief does not include a court filing or response from the company. The allegations in the lawsuit have not been tested in court.
The case now moves toward the lead-plaintiff deadline in mid-August, when the court will consider requests from shareholders seeking to direct the litigation.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()